High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Joost Vermaat, Pim Mutsaers, Sébastien Anguille, Maria Kuipers, Evelyne Willems, Tim Dekker, Peter Vandenberghe, Guillaume Dachy, Caron Jacobson, Michael Bishop, Martin Dreyling, Andreas Klein, Jon Arnason, Stavros Milatos, Harini Kothari, Daniela Buglio, Sandra Blum, Leonardo Chicaybam, Eva Santermans, Omotayo Fasan, Marie José Kersten
Institutions: Leiden University Medical Center, Erasmus MC, Erasmus MC Cancer Institute, Antwerp University Hospital, Amsterdam University Medical Centers, University of Amsterdam, Centre Hospitalier Universitaire de Liège, Universitair Ziekenhuis Leuven, KU Leuven, Cliniques Universitaires Saint-Luc, Dana-Farber Cancer Institute, University of Chicago, LMU Klinikum, Ludwig-Maximilians-Universität München, Tufts Medical Center, Beth Israel Deaconess Medical Center, Galapagos (Netherlands), Galapagos (Belgium)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417019936